Table 3 Multivariable analysis using the Cox regression model for survival outcomes.
PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
Crude | Adjusted* | Crude | Adjusted** | |||||
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age, years | ||||||||
< 65 (n = 116) | Reference | 0.926 | Reference | 0.315 | ||||
≥ 65 (n = 41) | 0.99 (0.82–1.19) | 1.21 (0.84–1.74) | ||||||
Sex | ||||||||
Male (n = 85) | Reference | 0.148 | Reference | 0.025 | Reference | 0.519 | ||
Female (n = 72) | 0.78 (0.56 –1.10) | 0.67 (0.48 –0.95) | 0.90 (0.65–1.24) | |||||
Primary site | ||||||||
Rt. colon (n = 42) | Reference | 0.079 | Reference | 0.214 | Reference | 0.126 | Reference | 0.147 |
Lt. colon (n = 115) | 1.40 (0.96–2.04) | 1.27 (0.87–1.87) | 1.33 (0.92–1.92) | 1.33 (0.90–1.96) | ||||
Previous treatment lines | ||||||||
2 (n = 84) | Reference | 0.133 | Reference | 0.328 | Reference | 0.212 | ||
≥ 3 (n = 73) | 1.29 (0.93–1.79) | 1.20 (0.83–1.75) | 1.23 (0.89–1.70) | |||||
RAS mutation | ||||||||
Wild (n = 74) | Reference | 0.015 | Reference | 0.125 | Reference | 0.011 | Reference | 0.594 |
Mutant (n = 83) | 0.66 (0.47–0.91) | 0.75 (0.51–1.09) | 0.66 (0.48–0.91) | 0.77 (0.55–1.09) | ||||
Previous targeted biological treatment | ||||||||
Yes (n = 87) | Reference | 0.011 | Reference | 0.004 | Reference | 0.002 | Reference | 0.002 |
No (n = 70) | 0.65 (1.10–2.14) | 0.61 (0.43–0.85) | 0.59 (0.42–0.82) | 0.59 (0.43–0.82) | ||||
Time from first diagnosis of metastatic disease to treatment | ||||||||
< 24 months (n = 74) | Reference | 0.043 | Reference | 0.018 | Reference | 0.154 | Reference | 0.103 |
≥ 24 months (n = 83) | 0.71 (0.51–0.99) | 0.67 (0.48–0.93) | 0.79 (0.57–1.09) | 0.76 (0.55–1.06) | ||||
